7.50
前日終値:
$7.74
開ける:
$7.79
24時間の取引高:
1.04M
Relative Volume:
0.63
時価総額:
$697.83M
収益:
$823.60M
当期純損益:
$-116.00M
株価収益率:
-5.7692
EPS:
-1.3
ネットキャッシュフロー:
$-107.30M
1週間 パフォーマンス:
-6.95%
1か月 パフォーマンス:
+8.70%
6か月 パフォーマンス:
-5.66%
1年 パフォーマンス:
-67.49%
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MYGN
Myriad Genetics Inc
|
7.50 | 720.17M | 823.60M | -116.00M | -107.30M | -1.30 |
![]()
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
![]()
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
![]()
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
![]()
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
2025-02-12 | 開始されました | Craig Hallum | Buy |
2024-12-10 | 開始されました | UBS | Neutral |
2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
2024-08-28 | 開始されました | Wells Fargo | Overweight |
2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
2024-06-03 | 再開されました | Jefferies | Underperform |
2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
2023-12-21 | 再開されました | Piper Sandler | Neutral |
2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
2023-12-14 | 開始されました | Guggenheim | Buy |
2023-12-13 | 開始されました | Wolfe Research | Outperform |
2023-07-05 | 再開されました | JP Morgan | Underweight |
2023-05-23 | アップグレード | Goldman | Sell → Buy |
2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
2022-10-06 | 開始されました | Stephens | Equal-Weight |
2021-10-15 | 再開されました | Cowen | Market Perform |
2021-06-15 | 開始されました | Raymond James | Mkt Perform |
2021-06-03 | 開始されました | Goldman | Sell |
2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
2019-03-12 | 繰り返されました | Needham | Strong Buy |
2019-01-03 | 開始されました | Needham | Strong Buy |
2018-11-30 | アップグレード | Goldman | Sell → Neutral |
2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2018-01-29 | 開始されました | Goldman | Sell |
2018-01-22 | 繰り返されました | Barclays | Equal Weight |
2018-01-05 | 開始されました | BTIG Research | Buy |
2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
2017-08-09 | 繰り返されました | Barclays | Equal Weight |
2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
2017-01-18 | 開始されました | Deutsche Bank | Sell |
2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know - Yahoo
Myriad Genetics: How knowing genetic risks can help women with their healthcare - KATV
Is Myriad Genetics Inc. (MYD) stock considered safe havenWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Using RSI to spot recovery in Myriad Genetics Inc.Market Growth Review & Capital Protection Trading Alerts - newser.com
When is the best time to exit Myriad Genetics Inc.Market Weekly Review & Free High Accuracy Swing Entry Alerts - newser.com
Applying Elliott Wave Theory to Myriad Genetics Inc.Portfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
News impact scoring models applied to Myriad Genetics Inc.Oil Prices & Free Risk Controlled Daily Trade Plans - newser.com
Measuring Myriad Genetics Inc.’s beta against major indicesMarket Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV - The Manila Times
Dr. Stitt, Jodi Lavery discuss cancer screening fears, genetic testing benefits survey - KOKH
Myriad Genetics Finalizes CFO Separation Agreement - TipRanks
Myriad Genetics (NASDAQ:MYGN) Shares Pass Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Public Employees Retirement System of Ohio Raises Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Why Myriad Genetics Inc. stock is popular among millennialsEarnings Summary Report & High Accuracy Trade Signal Alerts - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Will Myriad Genetics Inc. price bounce be sustainableJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
Will Myriad Genetics Inc. (MYD) stock deliver stable dividendsCEO Change & Long-Term Capital Growth Strategies - newser.com
Is Myriad Genetics Inc. stock attractive for passive investorsJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Heatmap analysis for Myriad Genetics Inc. and competitorsJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
Is Myriad Genetics Inc. (MYD) stock ideal for retirement investorsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
Should Dividend Investors Consider Tecil Chemicals and Hydro Power Ltd in 2025Automated Trading Signals & Create Passive Income With Smart Stocks - earlytimes.in
Myriad Genetics Inc Stock Analysis and ForecastDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics announces resignation of principal accounting officer - Investing.com
jscreen, TODAY Show & Mount Sinai Unite for Groundbreaking Cancer Genetic Screening Event in Honor of Breast Cancer Awareness Month - Yahoo Finance
United States Genomics Industryinvestments driving $115B - openPR.com
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack - The Globe and Mail
Myriad Genetics (NASDAQ:MYGN) Shares Down 5.2%Should You Sell? - MarketBeat
Is Myriad Genetics Inc a good long term investmentPortfolio Allocation Tips & Superior Capital Trading - Early Times
Assenagon Asset Management S.A. Buys 240,643 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges - MSN
Myriad Genetics and SOPHiA GENETICS partner on liquid biopsy test By Investing.com - Investing.com Canada
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy - The Manila Times
Myriad Genetics and SOPHiA GENETICS partner on liquid biopsy test - Investing.com
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):